AI heart test could speed up lifesaving device implants

NCT ID NCT07217236

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial is testing whether an artificial intelligence-enhanced electrocardiogram (AI-ECG) can better identify patients who need a cardiac implantable electronic device (like a pacemaker or defibrillator) compared to standard care. Over 11,000 participants will be randomly assigned to either the AI-ECG strategy or usual care. Those flagged as high-risk by the AI will receive a continuous heart monitor for up to 7 days. The goal is to see if the AI approach leads to more timely and appropriate device implantation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
AI-enhanced electrocardiogram (ECG) with continuous cardiac rhythm monitoring
What this could lead to
If successful, this AI strategy could help doctors more quickly and accurately identify patients who need a pacemaker or defibrillator, potentially preventing serious heart complications.
What could go wrong
This is a large but early-stage trial, and the AI may not prove better than standard care. There is also a risk of false positives leading to unnecessary procedures or false negatives missing patients who need treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARTIFICIAL INTELLIGENCE (AI) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Tri-Service General Hospital

    RECRUITING

    Taipei, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.